This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Remission

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Leukaemic myeloblasts in AML require cytotoxic agents which are highly toxic to normal marrow cells.

  • an example of most commonly used combination therapy is - an anthracycline + cytarabine
  • treatment is scheduled to exploit the slower regeneration time of leukaemic cells compared to normal cells
  • commonly, aplasia of the bone marrow results which may take 2-3 weeks to recover
  • intensive supportive care is essential because of the myelosuppression.
  • all material necessary for diagnostic tests should be harvested before commencing chaemotherapy
  • emergency leukapheresis may be required before induction chemotherapy in patients who present with excessive leukocytosis (2)

Induction chaemotherapy should be started as soon as (or preferably with minimal delay) the diagnostic work-up has been completed (1). Retrospective data have suggested that a delay of beyond 5 days to initiate therapy may have an adverse impact on the treatment outcome (1).

It is important to identify patients for allogeneic stem-cell transplantation early during induction (2).

Induction therapy in acute promyelocytic leukaemia (APL) should be complemented with all-transretinoic acid (ATRA) (2).

Patients who fail to respond to one or two cycles of therapy is categorised as refractory (2).

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.